|
|
Original Research Article
Characterization of
Celecoxib-Loaded Solid Lipid Nanoparticles Formulated
with Tristearin and Softisan 100
Ehab A Fouad1,2*,
Alaa Eldeen B Yassin3,4 and Hamdan N Alajami5
1Department of Pharmaceutics,
Almaarefa Colleges for Science and Technology, P.O Box
71666, Riyadh 11597, Saudi Arabia, 2Department
of Pharmaceutics, Faculty of Pharmacy, Assiut University
71526, Assiut, Egypt, 3Pharmaceutical
Sciences Department, College of Pharmacy-3163, King Saud
bin Abdulaziz University for Health Sciences, and King
Abdullah International Medical Research Center, Ministry
of National Guard, Health Affairs, Riyadh 11426, Saudi
Arabia, 4Department of Pharmaceutics, Faculty
of Pharmacy, AlAzhar University, Cairo, Egypt, 5Pharmaceutical
Care Division, King Faisal Specialist Hospital and
Research Centre, PO Box 3354 Riyadh 11211, Saudi Arabia
*For correspondence:
Email:
bahe2004@yahoo.co.uk; Tel:
+966 553889130
Received: 22 September 2014
Revised accepted: 1 January
2015
Tropical Journal of Pharmaceutical Research,
February 2015;
14(2):
205-210
http://dx.doi.org/10.4314/tjpr.v14i2.3
Abstract
Purpose: To prepare solid lipid
nanoparticles employing softisan 100 (SOFTI) or
tristearin (TS) as solid lipid carriers for celecoxib (CXB)
to overcome its dissolution challenge.
Methods: The solid lipid
nanoparticles (SLN) of CXB were prepared by ultrasonic
melt-emulsification technique. SLN was characterized
using differential scanning calorimetry (DSC), Fourier
transform infra spectroscopy (FTIR), as well as for
entrapment efficiency, particle size, zeta potential and
CXB release.
Results: The SLN formulations
exhibited high CXB entrapment efficiency (91.6 % for
SOFTI and 94.6 % for TS) while mean particle size was
181.0 ± 4.6 and 346.3 ± 3.8 nm for SOFTI and TS,
respectively. The DSC thermograms showed the
disappearance of CXB peak due to its molecular
distribution in the lipid nanoparticles while FTIR
spectra revealed physical interaction of CXB with the
tested lipids. The tendency of SOFTI to liberate CXB in
24 h was higher than that of TS (55.5 ± 1.07 vs 49.2 ±
2.94 %, p < 0.05). Drug release was by non-Fickian
mechanism.
Conclusion: Formulation of CXB in SLN
using TS or SOFTI produces sustained drug release
delivery that can overcome the dissolution limitation of
the drug and thus, improve its therapeutic efficacy.
Keywords: Celecoxib, Solid lipid
nanoparticles, Tristearin, Softisan, Dissolution
limitation, Sustained drug release |
